Over nearly 20 years, Jeff Aronin the chairman and CEO of Paragon Sciences has established himself among the top biotech and healthcare related entrepreneurs. Recently he has applied his expertise and energy towards investing in innovative biotech companies.
He realized his passion for healthcare early on in his career. He found his inspiration while shadowing a physician who chose to use treat a child who suffered constant seizures with medicine instead of brain surgery. His made him see the power that medicine has.
It was this passion that stayed with him throughout his career and led to his enthusiasm for science and building companies. In 2000, Jeff Aronin founded Ovation Pharmaceuticals Inc. With is successful strategy based in the need of the patients the company became a success in providing novel medicines. Nine years after the company was funded it was purchased by Lundbeck , Jeff Aronin was appointed to watch over the transition.
Over the past decade Jeff Aronin has been serving Paragon Bio sciences as chairman and CEO, still led with is patient driven passion. He has become one of the most successful leaders in bio science, and has contributed to both the development and approval of over a dozen medicines.
They focus in the identification of those diseases with the most need for a treatment. The research team will focuses in testing conditions that have not yet been explored. Then looks into important factors that could possibly lead to a novel treatment.
The development of medicine is a difficult business to get into. Although promising, The majority of the treatments that make it to clinicals fail. Regardless Jeff Aronin and his selective team always focus more on the treatments that have a great market potential.
Besides Paragon Biosciences he has also been the chairman of several other companies including : Paragon Pharmaceuticals, Castle Creek Pharmaceuticals, and finally Harmony Biosciences. He has remined confident in the company , as well as it’s continued growth. It has always and is expected to continue to move towards it’s goals of the release of new and innovative patient based treatments.
read more about jeffery aronin below